CureVac appoints Daniel Menichella as CEO of U.S. Subsidiary

Wednesday, May 3, 2017

CureVac AG, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based therapies, has announced the appointment of Daniel Menichella as CEO of CureVac Inc., its Boston-based U.S. subsidiary. Menichella, an experienced executive in the biotech industry, will develop CureVac’s U.S. organization with a clear focus on business and corporate development activities around CureVac’s versatile mRNA technology platform.

[Read More]